|
|
|
Corporate Profile: Soligenix
| Summary: |
Soligenix focused on the development of products to treat life-threatening side effects of cancer treatment, serious gastrointestinal diseases, and vaccines for selected bioterrorism agents.
|
| Address (HQ): |
29 Emmons Drive
Suite C-10
Princeton, NJ 08540 |
| Phone #'s (HQ): |
| Main |
(609) 538-8200 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax #'s (HQ): |
| Main |
(609) 452-6467 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| email: |
| Main |
not known
|
| Human
Resources |
hr@soligenix.com |
| Investor
Relations |
not known |
| Financial
information: |
| SNGX |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
